Details for Patent: 10,335,452

Which drugs does patent 10,335,452 protect, and when does it expire?

Patent 10,335,452 protects TERLIVAZ and is included in one NDA.

This patent has twenty-seven patent family members in fourteen countries.

Summary for Patent: 10,335,452

Title:	Method of treating patients with hepatorenal syndrome type 1
Abstract:	The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease. A patient identified as suffering from HRS-1 is tested to determine if the patient meets at least two out of three criteria, wherein the three criteria include a WBC<4 or >12 cells/μL; HR>90 bpm; and any one of HCO<21 mmol/L or PaCO<32 mmHg or >20 breaths per minute. If the patient meets at least two of the criteria, he or she is administered terlipressin in an amount effective to produce a reduction in serum creatinine of at least 1.0 mg/dL.
Inventor(s):	Jamil Khurram, Pappas Stephen Chris, Potenziano Jim
Assignee:	Mallinckrodt Hospital Products IP Limited
Application Number:	US14920392
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 10,335,452

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mallinckrodt Ireland	TERLIVAZ	terlipressin acetate	POWDER;INTRAVENOUS	022231-001	Sep 14, 2022		RX	Yes	Yes						A METHOD TO IMPROVE KIDNEY FUNCTION IN ADULTS WITH HEPATORENAL SYNDROME WITH RAPID REDUCTION IN KIDNEY FUNCTION

International Family Members for US Patent 10,335,452

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2015335855
Australia	2022288996
Canada	2965325